EDIT - TIDES USA 2025 Conference
May 19, 2025, 4:00:00 AM UTC
Summary
Editas Medicine will present preclinical data and participate in panel discussions at the TIDES USA 2025 Conference from May 19-22, focusing on oligonucleotide and peptide therapeutics. This conference is significant for the biotech sector, showcasing advancements in drug development and delivery technologies.
Company
EDITAS MEDICINE INC (EDIT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.editasmedicine.comSimilar Events
TIDES USA 2025 - Oral Presentation
Metagenomi will present an oral session on AI-guided discovery of CRISPR systems for therapeutic genome editing at TIDES USA 2025.
conference talkOral Presentation at ASGCT
Editas Medicine will present preclinical data on in vivo gene editing at the ASGCT Annual Meeting, focusing on innovative delivery methods and therapeutic strategies.
conference talkCodexis Oral Presentation: Oligonucleotide CMC at TIDES USA
Codexis, Inc. will deliver an oral presentation on sustainable and scalable enzymatic siRNA manufacturing at the TIDES USA conference in San Diego on May 21, 2025. Alison Moore, PhD, Chief Technical Officer, will discuss advances in oligonucleotide chemistry, manufacturing, and controls (CMC) for siRNA therapeutics. The presentation highlights Codexis’s enzymatic solutions for efficient RNA drug production, a key area for contract development and manufacturing organizations (CDMOs) and biopharma partners. TIDES USA is a leading industry event focused on oligonucleotide and peptide therapeutics.
conference talkPresentation of In Vivo HSC Preclinical Data
Editas Medicine plans to present further in vivo HSC preclinical data by year-end 2025, showcasing advancements in gene editing.
clinical readout